Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1Phase 1 1

Status

Active not recruiting 2Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Carcinoma, Non-Small-Cell Lung 687Breast Neoplasms 585Neoplasms 468Colorectal Neoplasms 300Prostatic Neoplasms 263Neoplasm Metastasis 257Melanoma 242Ovarian Neoplasms 228Recurrence 216Lung Neoplasms 203Multiple Myeloma 196Lymphoma, Non-Hodgkin 155Pancreatic Neoplasms 154Leukemia, Myeloid, Acute 142Carcinoma, Hepatocellular 141Stomach Neoplasms 137Lymphoma 131Carcinoma, Renal Cell 128Glioblastoma 118Squamous Cell Carcinoma of Head and Neck 113Head and Neck Neoplasms 113Lymphoma, Follicular 106Leukemia, Lymphocytic, Chronic, B-Cell 99Small Cell Lung Carcinoma 96Lymphoma, Large B-Cell, Diffuse 96Leukemia 96Brain Neoplasms 91Carcinoma 82Uterine Cervical Neoplasms 77Triple Negative Breast Neoplasms 73

Interventions

sipuleucel-T 1pamiparib 1gallium 68 PSMA-11 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × Metastatic Castration-Resistant Prostate Cancer (mCRPC) × Clear all
NCT05658003 2026-03-23

A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

Novartis

Phase 2 Active not recruiting
63 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT05670106 2026-02-13

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC

Novartis

Phase 2 Active not recruiting
62 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT06134232 2025-08-27

ProvONE

Dendreon

Phase 2 Recruiting
400 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT03712930 2021-11-17

Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency

BeiGene

Phase 2 Terminated
13 enrolled 11 charts
Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡